Levothyroxine, also known as L-thyroxine, is a manufactured form of the thyroid hormone thyroxine (T4).
The global Levothyroxine Sodium market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Levothyroxine Sodium market based on company, product type, end user and key regions.
This report studies the global market size of Levothyroxine Sodium in key regions like North America, Europe, China and Japan, focuses on the consumption of Levothyroxine Sodium in these regions.
This research report categorizes the global Levothyroxine Sodium market by top players/brands, region, type and end user. This report also studies the global Levothyroxine Sodium market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Mylan Laboratories, Inc.,
Farmak (Farmak Group N.V.)
Goldline Laboratories, Inc.
IBSA Institut Biochimique SA
Fresenius Kabi USA Llc
Piramal Critical Care Ltd.,
Cediprof, Inc.
Abbvie, Inc.
Takeda Pharmaceutical Company Ltd.
Merck KGaA
Stevens Pharmaceuticals, Inc.
Pfizer, Inc.
Teva Pharmaceuticals
Abbott Laboratories, Inc.
Sandoz (Novartis International AG)
Lloyd, Inc.
Levothyroxine Sodium market size by Type
Hypothyroidism
Goiter
Thyroid Cancer
Myxedema Coma
Levothyroxine Sodium market size by Applications
Hospitals
Clinic
Others
Market size by Region
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan